We present a cohort of individuals who reached CD4+ T cell counts of greater than 1,000 cells/mm3 (Hypers) after starting antiretroviral treatment (ART) and compared them with those who reached between 350 and 999 CD4+ T cells/mm3 (Concordants). Demographic data, immune recovery kinetics, T CD4+ subset phenotypes, and integrated HIV DNA were analyzed. Data from individuals living with HIV on their first ART regimen and after 48 months of follow-up were obtained. Immune phenotype by Flow Cytometry analysis on whole blood was performed, cytokines were measured, and integrated HIV-1 DNA was measured by polymerase chain reaction. From a total of 424 individuals, 26 Hypers (6.1%), 314 Concordants (74.1%), and 84 (19.8%) discordants were identified. Hypers had a higher proportion of CD4+-naive (Nv) T cells (37.6 vs. 24.8, p < .05), and a low proportion of CD4+ effector memory T cells (27.9 vs. 39.4, p < .05), with similar results found in CD8+ T cells. Hypers demonstrated a higher percentage of CD4+CD45RA+CD31neg cells with a lower response to interleukin-2 stimulation and a lower integrated HIV-1 DNA/CD4 ratio (1.2 vs. 2.89, p < .05). In Hypers, T cell recovery occurs very early after initiation of ART. Following this initial recovery state, their CD4+ T cell level homeostasis seems to be driven by nonthymic-central-Nv cells. This exceptional recovery is associated with a lower HIV reservoir, which may be related to an increase in noninfected CD4+ T cells. These patients could then be eligible candidates for cure trials.
Get full access to this article
View all access options for this article.
References
1.
GuihotA, TubianaR, BretonG, et al.: ALT-ANRS CO-15 study group; DECAMUNE study group. Immune and virological benefits of 10years of permanent viral control with antiretroviral therapy. AIDS, 2010; 24:614–617.
2.
Jensen-FangelS, PedersenL, PedersenC, et al.: Low mortality in HIV-infected individuals starting highly active antiretroviral therapy: A comparison with the general population. AIDS, 2004; 18:89–97.
3.
HuntPW, DeeksSG, RodriguezB, et al.: Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS, 2003; 17:1907–1915.
4.
AlthoffKN, JusticeAC, GangeSJ, et al.: North American AIDS Cohorts Collaboration on Research, Design (NA-ACCORD). Virologic and immunologic response to HAART, by age and regimen class. AIDS, 2010; 24:2469–2479.
5.
KaufmannGR, FurrerH, LedergerberB, et al.; Swiss HIV Cohort Study: Characteristics, determinants, and clinical relevance of CD4 T-cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis, 2005; 41:361–372.
6.
LokJJ, BoschRJ, BensonCA, et al.; ALLRT team: Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS, 2010; 24:1867–1876.
7.
DrondaF, MorenoS, MorenoA, CasadoJL, Pérez-ElíasMJ, AntelaA: Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected individuals with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis, 2002; 35:1005–1009.
8.
GoicoecheaM, SmithDM, LiuL, et al.: Determinants of CD4+ T-cell recovery during suppressive antiretroviral therapy: Association of immune activation, T-cell maturation markers, and cellular HIV-1 DNA. J Infect Dis, 2006; 194:29–37.
9.
MarchettiG, GoriA, CasabiancaA, et al.: Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected individuals with discordant immune-virological responses to HAART. AIDS, 2006; 20:1727–1736.
10.
LedermanMM, CalabreseL, FunderburgNT, et al.: Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis, 2011; 2041217–1226.
11.
CorbeauP, ReynesJ: Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood, 2011; 117:5582–5590.
12.
GaardboJC, HartlingHJ, GerstoftJ, NielsenSD: Incomplete immune recovery in HIV infection: Mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol, 2012; 2012:670957.
13.
DeeksSG, TracyR, DouekDC: Systemic effects of inflammation on health during chronic HIV infection. Immunity, 2013; 39:633–645.
14.
Antiretroviral Therapy Cohort Collaboration: Causes of death in HIV-1-infected individuals treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis, 2010; 50:1387–1396.
15.
KesselringA, GrasL, SmitC, et al.: Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected individuals receiving combination antiretroviral therapy. Clin Infect Dis, 2011; 52:1458–1465.
16.
SaracinoA, BrunoG, ScudellerL, et al.: Chronic inflammation in a long-term cohort of HIV-infected individuals according to the normalization of the CD4:CD8 ratio. AIDS Res Hum Retroviruses, 2014; 30:1178–1184.
17.
Serrano-VillarS, GutiérrezC, VallejoA, et al.: The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect, 2013; 66:57–66.
18.
Serrano-VillarS, Pérez-ElíasMJ, DrondaF, et al.: Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One, 2014; 9:e85798.
19.
BrenchleyJM, PriceDA, SchackerTW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12:1365–1371.
20.
RuedaCM, VelillaPA, ChougnetCA, MontoyaCJ, RugelesMT: HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS One, 2012; 7:e30307.
21.
TanR, WestfallAO, WilligJH, et al.: Clinical outcome of HIV-infected antiretroviral-naive individuals with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2008; 47:553–558.
22.
ZoufalyA, an der HeidenM, KollanC, et al.; ClinSurv Study Group: Clinical outcome of HIV-infected individuals with discordant virological and immunological response to antiretroviral therapy. J Infect Dis, 2011; 203:364–371.
23.
MussiniC, PintiM, BorghiV, et al.: Features of ‘CD4-exploders’, HIV-positive individuals with an optimal immune reconstitution after potent antiretroviral therapy. AIDS, 2002; 16:1609–1616.
24.
LeT, WrightEJ, SmithDM, et al.: Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med, 2013; 368:218–230.
25.
KuNS, SongYG, HanSH, et al.: Short communication: Factors influencing time to CD4(+) T-cell counts >200 cells/mm3 in HIV-infected individuals with CD4(+) T-cell <50 cells/mm3 at the time of starting combination antiretroviral therapy. AIDS Res Hum Retroviruses, 2012; 28:1594–1597.
26.
SakaguchiS, MiyaraM, CostantinoCM, HaflerDA: FOXP3+ regulatory T-cells in the human immune system. Nat Rev Immunol, 2010; 10:490–500.
27.
Guidelines for antiretroviral treatment for people living with HIV, Mexico, CENSIDA, Ministry of Health (in Spanish).
28.
TeixeiraL, ValdezH, McCuneJM, et al.: Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS, 2001; 15:1749–1756.
29.
KolteL, RyderLP, Albrecht-BesteE, JensenFK, NielsenSD. HIV-infected individuals with a large thymus maintain higher CD4 counts in a 5-year follow-up study of individuals treated with highly active antiretroviral therapy. Scand J Immunol, 2009; 70:608–613.
30.
TsukamotoH, Clise-DwyerK, HustonGE, et al.: Age-associated increase in lifespan of naive CD4 T-cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc Natl Acad Sci U S A, 2009; 106:18333–18338.
31.
MarzialiM, De SantisW, CarelloR, et al.: T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS, 2006; 20:2033–2041.
32.
LedermanMM, MargolisL: The lymph node in HIV pathogenesis. Semin Immunol, 2008; 20:187–195.
33.
PickerLJ, HagenSI, LumR, et al.: Insufficient production and tissue delivery of CD4+ memory T-cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med, 2004; 200:1299–1314.
34.
KovacsJA, LempickiRA, SidorovIA, et al.: Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med, 2001; 194:1731–1741.
35.
DouekDC, BettsMR, HillBJ, et al.: Evidence for increased T-cell turnover and decreased thymic output in HIV infection. J Immunol, 2001; 167:6663–6668.
36.
SirskyjD, ThèzeJ, KumarA, KryworuchkoM: Disruption of the gamma c cytokine network in T-cells during HIV infection. Cytokine, 2008; 43:1–14.
37.
JuffroyO, BugaultF, LambotteO, et al.: Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: Decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. J Virol, 2010; 84:96–108.
38.
PickerLJ: Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol, 2006; 18:399–405.
39.
GiorgiJV, LylesRH, MatudJL, et al.; Multicenter AIDS Cohort Study: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr, 2002; 29:346–355.
40.
GrossmanZ, Meier-SchellersheimM, SousaAE, VictorinoRM, PaulWE: CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause?. Nat Med, 2002; 8:319–323.
41.
SedaghatAR, GermanJ, TeslovichTM, CofrancescoJJr, JieCC, TalbotCCJr, SilicianoRF. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: Type I interferon-mediated disruption of T-cell dynamics. J Virol, 2008; 82:1870–1883.
42.
BarberDL, AndradeBB, SeretiI, SherA: Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none. Nat Rev Microbiol, 2012; 10:150–156.
43.
Zaragoza-MaciasE, CoscoD, NguyenML, Del RioC, LennoxJ: Predictors of success with highly active antiretroviral therapy in an antiretroviral-naïve urban population. AIDS Res Hum Retroviruses, 2010; 26:133–138.
44.
CostagliolaD, LacombeJM, GhosnJ, et al.: CD4+ cell count recovery in naïve individuals initiating cART, who achieved and maintained plasma HIV-RNA suppression. J Int AIDS Soc, 2014; 17(4Suppl 3):19481.
45.
Bernal MorellE, Serrano CabezaJ, Muñoz Á, et al.: The CD4/CD8 ratio is inversely associated with carotid intima-media thickness progression in human immunodeficiency virus-infected individuals on antiretroviral treatment. AIDS Res Hum Retroviruses, 2016; 32:648–653.
46.
BansalA, SterrettS, ErdmannN, et al.: Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts. AIDS, 2015; 29:2245–2254.
47.
MarchettiG, GazzolaL, TrabattoniD, et al.: Skewed T-cell maturation and function in HIV-infected individuals failing CD4+ recovery upon long-term virologically suppressive HAART. AIDS, 2010; 24:1455–1460.
48.
KimmigS, PrzybylskiGK, SchmidtCA, et al.: Two subsets of naive T helper cells with distinct T-cell receptor excision circle content in human adult peripheral blood. J Exp Med, 2002; 195:789–794.
49.
SongK, RabinRL, HillBJ, et al.: Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. Proc Natl Acad Sci U S A, 2005; 102:7916–7921.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
